This patent application appeared to have been abandoned through lack of timely action, but a petition to extend Examination was GRANTED on 17 May. The failure to respond was deemed to be inadvertent.
This is a significant development, imo. The Examiner had contended that combining NOX66 with chemotherapy would have been obvious, but Noxopharm's attorney responded that the claim was for the combination of NOX66 plus sub-therapeutic doses of chemotherapy; and provided proof that the combination was effective. There is no prior art that suggests the use of sub-therapeutic doses of chemo.
Looking good for Allowance, in my view.
- Forums
- ASX - By Stock
- Targeted Drug Delivery
This patent application appeared to have been abandoned through...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
-0.002(2.94%) |
Mkt cap ! $19.28M |
Open | High | Low | Value | Volume |
6.7¢ | 6.9¢ | 6.6¢ | $13.31K | 198.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1137 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 22400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1137 | 0.066 |
1 | 100000 | 0.064 |
3 | 47786 | 0.061 |
4 | 105033 | 0.060 |
2 | 120000 | 0.059 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 12000 | 2 |
0.080 | 12099 | 2 |
0.081 | 22345 | 2 |
0.083 | 40000 | 1 |
0.090 | 25689 | 3 |
Last trade - 15.50pm 28/06/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online